The views of New Zealand general practitioners and patients on a proposed risk assessment and communication tool: a qualitative study using Normalisation Process Theory.

Communication Equity General practice Medication harm Normalisation Process Theory Risk

Journal

Implementation science communications
ISSN: 2662-2211
Titre abrégé: Implement Sci Commun
Pays: England
ID NLM: 101764360

Informations de publication

Date de publication:
10 Feb 2021
Historique:
received: 19 02 2020
accepted: 01 02 2021
entrez: 11 2 2021
pubmed: 12 2 2021
medline: 12 2 2021
Statut: epublish

Résumé

Communicating risks of medication harm and obtaining informed consent is difficult due to structural barriers, language and cultural practices, bias and a lack of resources appropriately tailored for the health literacy of most patients. A decision support tool was proposed to alert prescribers of risk and provide tailored information for patients to facilitate informed decision-making with patients and their whānau (family) around medication use. Patient and prescriber co-design was used to ensure the tool was designed to best meet the needs of end-users and avoid increasing health inequity. This paper describes the first stage of the co-design process. Normalisation Process Theory (NPT) was used to prospectively evaluate the tool. Semi-structured interviews were held with fifteen patients (five Māori, five Pasifika and five NZ European) and nine general practitioners (two Māori and seven European). Three themes were identified, which related to the three NPT concepts most relevant to developing the tool. Theme 1 (coherence: meaning and sense making by participants) explored participants' understanding of prescribing safety, medication harm and risk, which is based on experience. Patients want as much information as possible about their medications and risk, but doctors find it difficult to communicate that information. Theme 2 related to the NPT concept of cognitive participation (commitment and engagement by participants) explored what participants thought about a prescribing decision support tool. Participants were cautiously optimistic, but worried about potential harm arising from its use. They also identified requirements for the tool and features to avoid. Theme 3 describes the collective action required for successful implementation of the tool; namely, culturally safe and trustworthy doctor-patient relationships. Patients and general practitioners provided different perspectives when prospectively evaluating the proposed risk assessment and communication tool. This co-design research identified important pre-requisites for the tool and features to avoid and novel ideas for the proposed tool. Overall participants supported the development of the proposed risk assessment and communication tool, but identified the important role that doctor-patient relationships would play to ensure successful implementation. The use of Māori and Pacific languages in the proposed tool may enhance engagement and understanding.

Sections du résumé

BACKGROUND BACKGROUND
Communicating risks of medication harm and obtaining informed consent is difficult due to structural barriers, language and cultural practices, bias and a lack of resources appropriately tailored for the health literacy of most patients. A decision support tool was proposed to alert prescribers of risk and provide tailored information for patients to facilitate informed decision-making with patients and their whānau (family) around medication use. Patient and prescriber co-design was used to ensure the tool was designed to best meet the needs of end-users and avoid increasing health inequity. This paper describes the first stage of the co-design process.
METHOD METHODS
Normalisation Process Theory (NPT) was used to prospectively evaluate the tool. Semi-structured interviews were held with fifteen patients (five Māori, five Pasifika and five NZ European) and nine general practitioners (two Māori and seven European).
RESULTS RESULTS
Three themes were identified, which related to the three NPT concepts most relevant to developing the tool. Theme 1 (coherence: meaning and sense making by participants) explored participants' understanding of prescribing safety, medication harm and risk, which is based on experience. Patients want as much information as possible about their medications and risk, but doctors find it difficult to communicate that information. Theme 2 related to the NPT concept of cognitive participation (commitment and engagement by participants) explored what participants thought about a prescribing decision support tool. Participants were cautiously optimistic, but worried about potential harm arising from its use. They also identified requirements for the tool and features to avoid. Theme 3 describes the collective action required for successful implementation of the tool; namely, culturally safe and trustworthy doctor-patient relationships.
CONCLUSION CONCLUSIONS
Patients and general practitioners provided different perspectives when prospectively evaluating the proposed risk assessment and communication tool. This co-design research identified important pre-requisites for the tool and features to avoid and novel ideas for the proposed tool. Overall participants supported the development of the proposed risk assessment and communication tool, but identified the important role that doctor-patient relationships would play to ensure successful implementation. The use of Māori and Pacific languages in the proposed tool may enhance engagement and understanding.

Identifiants

pubmed: 33568225
doi: 10.1186/s43058-021-00120-1
pii: 10.1186/s43058-021-00120-1
pmc: PMC7877107
doi:

Types de publication

Journal Article

Langues

eng

Pagination

16

Subventions

Organisme : Health Research Council of New Zealand
ID : 18/031

Références

Drug Saf. 2003;26(1):1-11
pubmed: 12495359
Health Policy. 2018 Aug;122(8):837-853
pubmed: 29961558
Eur J Cancer Care (Engl). 2016 Mar;25(2):225-30
pubmed: 26918687
BMJ. 2003 Sep 27;327(7417):745-8
pubmed: 14512489
J Epidemiol Community Health. 2011 May;65(5):454-60
pubmed: 20466707
Ethn Dis. 2019 Feb 21;29(Suppl 1):187-192
pubmed: 30906168
Psychooncology. 2015 Nov;24(11):1398-406
pubmed: 25970704
J Med Internet Res. 2015 Jan 13;17(1):e19
pubmed: 25586865
J Epidemiol Community Health. 2013 Feb;67(2):190-3
pubmed: 22875078
Lancet. 2006 Jun 10;367(9526):1920-5
pubmed: 16765761
N Z Med J. 2019 Mar 29;132(1492):8-10
pubmed: 30921306
Patient Educ Couns. 2014 Mar;94(3):291-309
pubmed: 24305642
N Z Med J. 2018 Nov 9;131(1485):27-47
pubmed: 30408816
JAMA. 2016 Apr 5;315(13):1329-30
pubmed: 26940610
N Z Med J. 2013 Oct 18;126(1384):7-11
pubmed: 24162626
BMC Health Serv Res. 2018 Apr 2;18(1):230
pubmed: 29609656
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
Int J Equity Health. 2017 Feb 10;16(1):32
pubmed: 28222736
Int J Equity Health. 2019 Oct 12;18(1):151
pubmed: 31604434
N Z Med J. 2017 Nov 10;130(1465):96-103
pubmed: 29121628
Int J Clin Pharm. 2019 Oct;41(5):1272-1281
pubmed: 31313004
J Prim Health Care. 2012 Dec 01;4(4):288-93
pubmed: 23205377
PLoS One. 2015 Sep 23;10(9):e0138511
pubmed: 26398658
Psychother Psychosom. 2018;87(4):204-210
pubmed: 29895014
J Paediatr Child Health. 2012 Mar;48(3):193-201
pubmed: 21996021
Implement Sci. 2014 Jan 02;9:2
pubmed: 24383661
BMC Health Serv Res. 2016 Aug 15;16(a):386
pubmed: 27527614
Ann Intern Med. 2011 Jul 19;155(2):97-107
pubmed: 21768583
Soc Sci Med. 2012 Feb;74(3):408-415
pubmed: 22204840
Open Womens Health J. 2010;(4):7-17
pubmed: 23390467
Behav Med. 1998 Summer;24(2):81-8
pubmed: 9695899
J Health Serv Res Policy. 1996 Apr;1(2):93-103
pubmed: 10180855
BMJ Open. 2018 Oct 31;8(10):e026335
pubmed: 30385450
J Gen Intern Med. 2017 Aug;32(8):863-870
pubmed: 28185201
BMC Health Serv Res. 2012 Sep 18;12:322
pubmed: 22985266
J Gen Intern Med. 2006 Jan;21 Suppl 1:S21-7
pubmed: 16405705
Aust N Z J Public Health. 2019 Feb;43(1):75-80
pubmed: 30296819
Patient Educ Couns. 2008 Dec;73(3):526-35
pubmed: 18752915
Aust N Z J Public Health. 2010 Apr;34(2):193-9
pubmed: 23331365
Annu Rev Public Health. 2006;27:167-94
pubmed: 16533114
Res Social Adm Pharm. 2017 Nov;13(6):1186-1190
pubmed: 27818214
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Am Med Inform Assoc. 2006 Mar-Apr;13(2):138-47
pubmed: 16357358
Implement Sci. 2013 Apr 11;8:43
pubmed: 23578304
BMC Med Inform Decis Mak. 2017 Apr 10;17(1):36
pubmed: 28395667
Can Fam Physician. 2002 Jan;48:104-10
pubmed: 11852597
BMC Med. 2010 Oct 20;8:63
pubmed: 20961442
J Prim Health Care. 2018 Mar;10(1):39-43
pubmed: 30068450
PLoS One. 2013 Nov 21;8(11):e80194
pubmed: 24278258
Lancet. 2019 Aug 3;394(10196):432-442
pubmed: 31379334
Gerontology. 2015;61(3):195-202
pubmed: 25428287
N Z Med J. 2012 Nov 09;125(1365):8-15
pubmed: 23254495
Fam Pract. 1998 Aug;15(4):296-300
pubmed: 9792343
Drugs Ther Perspect. 2015 Feb;31(2):68-76
pubmed: 25750513
Ergonomics. 2015;58(1):33-49
pubmed: 25323570
BMC Health Serv Res. 2006 Jul 07;6:86
pubmed: 16827928
Implement Sci. 2018 Jun 7;13(1):80
pubmed: 29879986
Implement Sci. 2008 Dec 31;3:57
pubmed: 19117509
Int J Equity Health. 2019 Oct 30;18(1):168
pubmed: 31666134
J Epidemiol Community Health. 2010 Feb;64(2):117-23
pubmed: 20056966
BMJ Qual Saf. 2019 Jun;28(6):499-510
pubmed: 30301874
Pharmacol Rev. 2015 Jul;67(3):697-730
pubmed: 26126649
J Gen Intern Med. 2019 Apr;34(4):604-617
pubmed: 30734188
Med Care. 2017 Sep;55 Suppl 9 Suppl 2:S16-S23
pubmed: 28806362
Gerontologist. 2019 Jan 9;59(1):e1-e15
pubmed: 29750241
BMJ Qual Saf. 2015 Mar;24(3):228-38
pubmed: 25616279
Int J Equity Health. 2019 Nov 14;18(1):174
pubmed: 31727076
Health Promot Int. 2009 Sep;24(3):285-96
pubmed: 19372101
Cochrane Database Syst Rev. 2017 Apr 12;4:CD001431
pubmed: 28402085
J Prim Health Care. 2018 Mar;10(1):11-15
pubmed: 30068445
BMC Psychiatry. 2012 May 30;12:53
pubmed: 22646974

Auteurs

Sharon Leitch (S)

University of Otago Medical School, Dunedin, New Zealand. sharon.leitch@otago.ac.nz.

Alesha Smith (A)

School of Pharmacy, University of Otago, Dunedin, New Zealand.

Sue Crengle (S)

University of Otago Medical School, Dunedin, New Zealand.

Tim Stokes (T)

University of Otago Medical School, Dunedin, New Zealand.

Classifications MeSH